The *Escherichia coli* maltodextrin-binding protein (MBP) is a member of the periplasmic binding protein family and functions in the transport of maltodextrins. The role of MBP is to bind maltodextrins at the outer membrane porin LamB and release them to the MalEFK transport apparatus in the inner membrane. A high affinity is required when in position at the outer membrane to bind maltodextrins, but the sugar must be released at the inner membrane when it docks with the transport apparatus. It accomplishes this in part by having two conformations, the closed form which favors binding and the open form which favors release. In addition, MBP acts as a sensor for maltodextrins in the chemotactic system, interacting with the signal transduction protein Tar to regulate motility. The affinity characteristics of MBP for maltodextrins in vivo have been selected to optimize these functions.

MBP is also a useful tag for the expression and purification of recombinant proteins in three ways: improving translational expression, providing an affinity purification strategy, and enhancing the solubility of many refractory proteins. Microbial expression systems such as those developed for *E. coli* are often the first choice for preparing large amounts of recombinant proteins due to their low cost and high yield. To facilitate the expression and purification of a target protein, one method that is in common use is to fuse a tag to the protein. A good tag has properties that facilitate high-level translational expression when fused to the target protein, as well as providing a simple one-step affinity purification that allows the target protein to be purified from the expression milieu. MBP is commonly used as a tag for expression and purification of foreign proteins produced in *E. coli*. Fusion of the C terminus of MBP to the N terminus of a target protein facilitates the expression of the fusion protein in *E. coli*. MBP and MBP fusions can be purified in a single step by binding to a chromatography matrix containing any of a number of glucose-α1→4-glucose polysaccharides such as amylose, starch or other maltodextrins. MBP is also useful as a "solubility tag." Proteins that are soluble in their native host are sometimes insoluble when expressed in *E. coli*. For many of these proteins, fusion to MBP renders them soluble (Kapust and Waugh [@CR8]).

MBP has previously been engineered for changes in binding affinity and specificity. The Kd of MBP for maltose and maltotriose in vitro is about 2 and 0.4 µM, respectively (Miller et al. [@CR11]; Telmer and Shilton [@CR18]). The X-ray crystal structure of MBP shows that MBP consists of two domains, with a cleft between the domains where the polysaccharide binds (Duan and Quiocho [@CR3]; Sharff et al. [@CR15]; Spurlino et al. [@CR16]). The domain that contains the N terminus is named domain I, and the domain that contains the C terminus is named domain II. Three loops cross between the two domains to form a hinge. Researchers have used the structure of MBP to make directed mutations in order to alter the binding properties of MBP. Using directed mutagenesis based on the structure, MBP has been engineered to bind zinc (Marvin and Hellinga [@CR9]). In addition, two reports have described using the structure to make directed mutations to the region behind the hinge that increases the affinity of MBP for maltose and maltotriose (Marvin and Hellinga [@CR10]; Telmer and Shilton [@CR18]). However, the mutations made using this approach can decrease MBP's ability to enhance the solubility of proteins to which it is fused, thus reducing its utility as a tag (Nallamsetty and Waugh [@CR12]).

In this study, we explored the possibility that there might exist mutations in MBP that alter its conformation and/or its affinity for maltodextrins without compromising its solubility-enhancing properties, either by subtle changes in the hydrophobic core of the protein or by surface changes that do not compromise its folding or solubility. We set out to identify such mutations by random mutagenesis and screening for mutants that out-performed wild-type MBP2 in an affinity purification.

Materials and methods {#Sec1}
=====================

**Materials** Restriction enzymes, β-agarase, DNA polymerases, T4 ligase, antarctic phosphatase, Litmus 38, the pMAL Protein Fusion and Purification System including pMAL-c2X, pMAL-c2G, and pMAL-c4X, the USER Friendly Cloning kit, amylose resin, anti-MBP monoclonal antibody linked to horseradish peroxidase, and synthetic oligonucleotides were obtained from New England Biolabs. The nuclease Benzonase from *Serratia marcescens* was purified as an MBP fusion protein and separated from MBP by digestion with factor Xa protease, using the pMAL system (data not shown). Whatman Unifilter 800 microplates with filter bottoms and Immulon 2HB microplates were purchased from VWR. The MinElute DNA Extraction and QIAquick Spin kits were purchased from Qiagen. The detergent MEGA 10 was purchased from Dojindo. Hen egg white lysozyme and Coomassie brilliant blue R were purchased from Sigma--Aldrich. Disposable polypropylene columns (\#732-6008) were purchased from BioRad; 10--20% gradient gels were purchased from either Daiichi or Invitrogen/Novex.

**Strains and plasmids** Host strains TB1, ER1992, ER2502, ER2984, NEB 5-alpha, NEB Turbo, and NEB Express were obtained from New England Biolabs. The source of the *Bacillus circulans* chitin binding domain (CBD) was pMB50, kindly provided by M. Xu (see [Supplemental data](#MOESM1){ref-type=""}). The construction of the pMAL derivatives pSN1578 and pIH1684 is described in the supplemental data. The pMAL-DHFR and pMAL-GAPDH plasmids were constructed using a protocol similar to ligation-independent cloning (Aslanidis and de Jong [@CR2]), except in this case, the overhangs created were short and still require ligase to produce a transformable plasmid (see [Supplemental data](#MOESM1){ref-type=""}). The DHFR and GAPDH regions from the resulting plasmids were then transferred into other pMAL derivatives as AvaI, SbfI or AvaI, HindIII fragments.

**PCR mutagenesis** Random PCR mutagenesis was carried out as described in (Fromant et al. [@CR6]). Briefly, four reactions were carried out, each with three of the four nucleotides at a concentration of 0.2 mM and the fourth nucleotide at 0.5 mM. PCR was performed using Taq polymerase in the presence of 6 mM MgSO~4~. For the first library, the *malE* gene was amplified with the primers 5′GGAGACAUGAATTCAATGAAAATCGAAGAA and 5′GGGAAAGUAAGCTTAATCCTTCCCTCGATC, using pMAL-c2X as a template. PCR fragments were cloned into linearized pNEB208A using the USER Friendly Cloning Kit, following the manufacturer's instructions. For the second library, the *malE* gene was amplified with the primers 5′CACGAGCAATTGACCAACAAGGAC and 5′GATCGAGAGCTCGAATTAGTCTGC. Both the PCR product and pIH1684 were cut with MfeI and SacI and gel purified, and the two fragments were ligated. Transformants from each library were grown overnight in 0.9 mL LB + 10 uM IPTG and 100 ug/mL ampicillin and then lysed by adding 0.1 mL of a detergent/lysozyme/nuclease solution, giving a final concentration of 50 mM Tris--Cl pH 8.0, 50 mM NaCl, 0.2 mM EDTA, 0.2 mg/mL lysozyme, 0.3% MEGA-10, and 20 U/mL of Benzonase (to reduce viscosity; modified Kunitz units (Friedhoff et al. [@CR5])) and incubating for 2 min at room temperature.

**Screening MBP mutants by affinity purification** Of the extracts prepared, 0.7 mL, as described above, was applied to 100 uL of amylose resin in a well of a Unifilter 800 microplate, and each well was washed with 2 mL of 20 mM Tris--Cl, 0.2 M NaCl, 1 mM EDTA, pH 7.4 (column buffer, CB) containing 0.2% Tween 20, then with 2 mL of CB without Tween 20, and finally with 1 mL of 10 mM sodium phosphate, 0.2 M NaCl, 1 mM EDTA, pH 7.2. The protein bound to the amylose resin was then eluted with 0.2 mL of 10 mM maltose, 10 mM sodium phosphate, 0.2 M NaCl, 1 mM EDTA, pH 7.2.The eluate was transferred to an Immulon 2HB microplate and incubated overnight at 4°C. The microplate wells were then emptied, washed twice with 20 mM Tris--Cl, 150 mM NaCl, pH 7.5 (TBST), then blocked with 0.36 mL TBST + 3% bovine serum albumin for 1 h at 37°C. The wells were washed twice with TBST, then 0.2 mL of a 1:2,000 dilution of anti-MBP monoclonal antibody linked to horse radish peroxidase in TBST + 3% bovine serum albumin was added to each well and the plate incubated at 37°C for 1 h. The wells were emptied and then washed three times with TBST. The wells were developed with 0.01% *o*-phenylenediamine, 0.003% hydrogen peroxide in water. The detection reaction was stopped by adding 0.025 mL 4 M H~2~SO~4~, and wells were assayed spectrophotometrically at 490 nm. Cells were recovered from samples corresponding to lysates that showed higher binding and elution as compared to wild-type MBP. These candidates were grown and retested to confirm the higher binding and elution. A list of the mutations is given in Table S[1](#MOESM4){ref-type=""}.

**Subcloning and separation of mutations** For the first library, the genes for candidate MBP mutants were processed with PCR from pNEB208A using the primers 5′ GACTCATATGAAAATCGAAGAAGGTAAACTGGTAATCTGGATTAACGGC and 5′ ATATAAGCTTTCACCTTCCCTCGATCCCGAGGT. The PCR fragment was cut with NdeI and HindIII and ligated into the pMAL derivative pIH1684 cut with the same enzymes. The second library was constructed directly in pIH1684, so testing proceeded without needing to subclone. Of the 25 mutants obtained in the screen, ten had silent mutations in addition to one or more missense mutations; the silent mutations were ignored for this analysis. Five were identical in sequence to another mutant, presumed to be siblings, and dropped. Nine had a single missense mutation. The remaining 11 had from two to five missense mutations. The mutations in the multiple mutants were reconstructed separately by either subcloning, when appropriate sites were available, or four primer mutagenesis as described in Guan and Kumar [@CR7]. The PCR fragments produced were ligated into pIH1684.

**Small-scale affinity purification of MBP and MBP fusions** A 200-mL culture of each variant of MBP2 to be tested was grown in LB + 0.1% glucose and 100 µg/mL ampicillin to early log phase, then induced by addition of IPTG to a final concentration of 0.3 mM. The cells were harvested after 2 h and resuspended in 5 mL CB, sonicated, and clarified at 9,000×*g* for 30 min. A 1.6-mL sample of the supernatant was diluted to 8 mL with CB and applied to a 1-mL amylose column. The column was washed with 16 mL CB and eluted with 4 mL of CB + 10 mM maltose. The protein in the eluate was quantitated by spectrophotometry at 280 nm (A~280~ of 1 corresponds to 0.66 mg/mL). Values for wild-type (included in all experiments as a control) are the average of 19 experiments, and values for A312V (included as an additional control in most experiments) are the average of 16 experiments; all others are the average of 2--8 experiments and are expressed as % yield relative to wild-type in the same experiment, then normalized to the overall wild-type average.

**Solubility enhancement of MBP fusions** A 10-mL culture of NEB Express containing the pMAL-DHFR or pMAL-GAPDH derivative was grown to 2 × 10^8^ cells/mL in LB + 0.1% glucose and 100 µg/mL ampicillin, induced with 0.3 mM IPTG, incubated for an additional 2 h, then cells were harvested by centrifugation at 3,000×*g* in a microfuge. Each pellet was resuspended in 1 mL of CB and lysed by sonication. The lysate was centrifuged for 2 m at 14,000×*g*, and the supernatant was removed and designated the soluble fraction. The pellet was resupended in 1 mL of the same buffer and designated the insoluble fraction. A sample (4 uL) of each fraction was run on SDS--PAGE for each strain, the gels were dried and scanned, and the amount of MBP fusion protein in each lane was quantitated using ImageJ (Abramoff et al. [@CR1]). Results are expressed as a ratio of soluble MBP fusion protein to total MBP fusion protein present in the soluble and insoluble lanes.

**Determination of dissociation constants** Kd measurements were made by measuring maltose-induced fluorescence quenching (Miller et al. [@CR11]) using a Perkin--Elmer LS50B luminescence spectrophotometer. All measurements were carried out at room temperature (25--26°C), at a protein concentration of 15 µg/mL (0.32 µM) and an excitation wavelength of 290 nm. Emission scans were done with excitation slit width of 2.5 nm and an emission slit width of 5.0 nm. Titrations with maltose or maltotriose were carried out with excitation and emission slit widths of 5.0 nm, and an emission wavelength of 330 and/or 350 nm, depending on the mutant (see "[Results](#Sec2){ref-type="sec"}"). The data were plotted as percent quenched vs. input maltose/maltotriose concentration, and the dissociation constant determined by a curve-fit using the equilibrium binding equation in Miller et al. [@CR11] and the software KaleidaGraph 4 (Synergy Software).

Results {#Sec2}
=======

**MBP mutations that affect affinity purification** We undertook the present study to see if we could identify mutations in MBP that would increase its ability to bind and elute from an amylose affinity resin. We hoped that by screening random mutants for this property, we might identify mutations that affect the affinity without altering the properties that make MBP a useful affinity tag, most importantly its ability to enhance the solubility of proteins that tend to be insoluble when expressed in *E. coli*. Wild-type MBP of *E. coli* is made as a precursor with an N-terminal signal peptide and secreted into the periplasm where the signal peptide is removed. For this study, we used a cytoplasmic derivative of MBP called MBP2, which differs from the mature MBP protein in that it has a methionine at the N terminus in place of the signal peptide, and the last four residues are replaced by a 20-residue-engineered linker and residues encoded by a MCS on the pMAL vectors. We used error-prone PCR to create mutant alleles of the gene that encodes MBP2 and screened about 4,000 isolates from two independent libraries of MBP2 mutants. Among the 19 mutations obtained, we identified substitutions at 14 positions in the amino acid sequence and one frameshift mutation. The frameshift was in the last base of the *malE* gene present in our construct and affected the residues that are encoded by the engineered linker. Many of the mutants contained multiple mutations. We separated the mutations and tested them individually to identify which of the mutations were responsible for the increase in yield from the affinity purification relative to MBP2 (high-yield phenotype). In all cases but two, we found that a single mutation could account for the high yield of the original mutant (data not shown). However, we cannot rule out that the additional mutations that have no phenotype when tested alone could contribute to the phenotype of the original mutant. In the two cases where more than one mutation contributed to the phenotype, we found other variants of MBP2 that contained just one of each of the changes. The locations of the mutations in the primary sequence are shown in Fig. [1](#Fig1){ref-type="fig"}, while Fig. [2](#Fig2){ref-type="fig"} shows a cartoon of the structure of MBP and the location of the residues mutated. All but one of the mutations are located between residues 68 and 115 in the N-terminal half of the sequence and between residues 303 and 343 in the C-terminal half; the final mutation, the Δ2682 deletion, creates a frameshift which affects residues from 367 to the end. There is a hotspot for mutations in helix 14 of domain I, which contains a number of residues that interact with domain II in the open conformation (Marvin and Hellinga [@CR9]; Telmer and Shilton [@CR18]). Fig. 1Sequence of MBP2 and location of mutations. Mutations are indicated in *bold* under the amino acid sequence. *Δ2682* indicates a deletion of a thymine at position 2682 in the DNA sequence, which leads to a frameshift of the subsequent residues in MBP2. Secondary structural elements are indicated above the sequence, *arrows* for β-sheets and helices for α-helices, according to the PDB file 1ANF (Spurlino et al. [@CR16]). The β-sheets are labeled with a *letter* to indicate the structural element and a *number* to indicate the strand in that element; e.g., β-sheet "A" is made up of two strands, A1 and A2. Helices are indicated by a *number*. The numbering of the mutations we obtained ignores the N-terminal methionine present in MBP2, to simplify comparison to the structure and the previous literature. The sequences corresponding to the hinges between the two domains are indicated as *bold letters* embedded in the sequenceFig. 2MBP structure and location of mutated residues. Structure from PDB file 1ANF rendered using PyMOL. Domain I is in *green*, domain II is in *yellow*, hinge regions are in *cyan*, and maltose carbons are in *salmon*. View is from the opposite side from the binding cleft. **a** Cartoon of MBP structure. **b** Location of mutated residues. Stereo view of the α-carbon trace of MBP, with the residues where mutants were obtained in *crimson*

**Effect of mutations on affinity purification of MBP2 and a fusion derivative** After the initial identification of the mutations, we retested each MBP2 derivative in a 1-mL column format. In order to test whether the increased yield of MBP2 would carry over to problematic fusion proteins, we also constructed pMAL vectors that would express an MBP2-chitin binding domain fusion (MBP2-CBD) for each of the mutations. Under the conditions we used, approximately 95% of the wild-type derivatives of both MBP2 and MBP2-CBD failed to bind or prematurely eluted from the amylose resin during the wash. The yield for wild-type MBP2 in these experiments was 2.3 ± 0.85 mg/L; the yield for wild-type MBP2-CBD was 3.7 ± 1.1 mg/L (average of 19 experiments; error is the 95% confidence interval). All 19 mutations were tested as MBP2 and MBP2-CBD fusions, and the results are shown in Fig. [3a](#Fig3){ref-type="fig"}. The mutations increased the yield of MBP2 from 1.3- to 15-fold over wild-type MBP2. With the exception of V302L, Y307C, and M321K, the mutations that led to an increase in MBP2 yield also led to an increase MBP2-CBD yield; unlike the V302L derivative, the V302A derivative of MBP2-CBD did give an increased yield. Fig. 3**a** Yield of MBP2 and MBP2-CBD derivatives. MBP2, MBP2-CBD, and their mutant derivatives were purified on a 1-mL amylose column as described in "[Materials and methods](#Sec1){ref-type="sec"}" and the results graphed as the yield of protein relative to the yield of wild-type MBP2 in a purification performed in parallel. Values for wild-type MBP2 and A312V are the average of 19 experiments (included as controls in all experiments); values for the remaining mutants are the average of 2--8 experiments. *Error bars* are 95% confidence intervals. **b** Cells expressing MBP2-DHFR or MBP2-GAPDH and their mutant derivatives were lysed and fractionated into soluble and insoluble fractions, and the amount of soluble and insoluble fusion protein was quantitated, as described in "[Materials and methods](#Sec1){ref-type="sec"}." Results are expressed as the ratio of soluble MBP fusion protein to total MBP fusion protein. Values for wild-type and A312V are the average of 19 and 16 experiments, respectively (included as controls in all or most experiments, respectively); all others are the average of three to four experiments and are expressed as % soluble relative to wild-type in the same experiment, then normalized to the overall wild-type average. *Error bars* are 95% confidence intervals

**Mutations that retain the solubility enhancement properties of MBP fusions** In order to see if the mutations affected the ability of MBP2 to enhance the solubility of fused proteins, we constructed pMAL plasmids that expressed MBP2 fused to human dihydrofolate reductase (MBP2-DHFR) for each of the mutations. We chose DHFR from among the proteins whose solubility had previously been shown to be enhanced by MBP (Kapust and Waugh [@CR8]). Figure [3b](#Fig3){ref-type="fig"} shows the results of this solubility assay. Five out of the 19 mutations retain all or most of the solubility enhancement property of MBP2 for this fusion: F67L, A312V, I317V, Q325R, and V343M. To test if the solubility-enhancement properties of these five mutations might extend to other proteins, we tested them as fusions to murine glyceraldehyde phosphate dehydrogenase (MBP-GAPDH), another protein whose solubility has been shown to be enhanced by MBP (Kapust and Waugh [@CR8]). All of these mutations, with the possible exception of Q325R, were able to solubilize GAPDH about as well as wild-type MBP2 (Fig. [3b](#Fig3){ref-type="fig"}).

**Combinations of mutations** We made one class of double mutants to test whether the loss of solubility enhancement due to a change in one residue could be rescued by a second mutation, by testing the solubility of MBP2-DHFR derivatives with the A312V mutation along with substitutions at N323 and N332. The original mutations at these residues, N323Y and N332I, reduced the solubility of MBP2-DHFR, while A312V was neutral or slightly increased its solubility. We reasoned that another hydrophilic side chain as a substitute for asparagine would be more likely to retain solubility enhancement, and the addition of A312V might provide some additional increase in the solubility properties of the mutant. Thus, we tested the double mutants A312V N323Q, A312V N323R, A312V N332Q, and A312V N332R. All four of these mutants had a greatly reduced ability to solubilize the fused DHFR compared to wild-type MBP2, one fifth that of wild-type or less (data not shown).We constructed another class of double mutants to see if two mutations that individually provided good solubility could be combined to produce a double mutant that retained the solubility property while also maintaining increased affinity. The double mutants we constructed were A312V I317V, A312V I317A, A312V Q325R, and A312V Q325K. The results are shown on Table [1](#Tab1){ref-type="table"}. The A312V Q325*X* mutants showed reduced ability to enhance the solubility of DHFR compared to wild-type, but the A312V I317V and A312V I317A mutants had solubility properties at least equal to wild-type. Encouraged by these results, we tested the double mutants for their yield of MBP2 and MBP2-CBD in the amylose affinity purification. Both the A312V I317V and, to a lesser degree, the A312V I317A mutant gave increased yields in the affinity purification compared to wild-type for both the MBP2 and MBP2-CBD derivatives (Table [1](#Tab1){ref-type="table"}). Table 1Solubility and yields of double mutants Solubility was calculated as in Fig. [3](#Fig3){ref-type="fig"}MBP2 derivative% MBP2-DHFR solubleMBP2 yield (mg/L)MBP2-CBD yield (mg/L)wt62%2.3 ± 0.53.5 ± 0.9A312V I317V67%31 ± 4.844 ± 3.1A312V I317A74%16 ± 3.922 ± 4.1A312V Q325R35%NDNDA312V Q325K35%NDNDFor solubility, the value for wt is the average of 19 experiments, and the values for the mutants are from two to three experiments. For yields, the value for wt is from 19 experiments, and the values for the mutants are the average of six experiments; errors indicate the 95% confidence interval*ND* not determined

**Dissociation constants for MBP mutants** We measured the affinity for maltose and maltotriose for each mutant MBP that retained the ability to enhance the solubility of DHFR. The method we used was ligand-induced fluorescence quenching of tryptophan, essentially as described (Miller et al. [@CR11]). Emission wavelength scans were performed for each mutant, and we discovered that the shape of the curves for the MBP2 derivatives we tested was slightly different from that described in the literature for MBP (Fig. S[2](#MOESM3){ref-type=""}). For fluorescence quenching with maltose, we chose an emission wavelength of 350 nm. For fluorescence quenching with maltotriose, we used either 330 and/or 350 nm, depending on the shape of the emission spectrum. In cases where both 330 and 350 nm titrations were done, the results were in good agreement. We determined the dissociation constants using curve-fitting software with the standard equilibrium equation as the model. The results are given in Table [2](#Tab2){ref-type="table"}. In most cases, those mutants that show an increased yield in the affinity purification also show a decrease in the Kd. The exceptions are F67L, where the Kds for both maltose and maltotriose are increased relative to MBP2, and V343M, where the Kd for maltotriose is increased. We presume that the Kd for maltotriose is more relevant, since the amylose column is derivatized with maltodextrins of chain length greater than three. Table 2Dissociation constants of a subset of the mutant proteinsKd maltoseKd maltotrioseMBP21.49 ± .010.38 ± .02F67L7.00 ± .71.40 ± .2A312V0.23 ± .020.11 ± .01I317V0.60 ± .080.20 ± .03Q325R0.52 ± .050.31 ± .02V343M0.92 ± .060.54 ± .05A312V I317V0.16 ± .020.03 ± .01A312V I317A0.86 ± .060.19 ± .03Values are calculated as described in "[Materials and methods](#Sec1){ref-type="sec"}"; error is calculated from the curve-fitting software, and is not an experimental error

Discussion {#Sec3}
==========

Using random mutagenesis of the sequence encoding the MBP2 protein, we were able to find mutations in MBP2 that enhance its yield in an affinity purification. Nineteen out of the 4,000 mutants screened, or about 0.5%, showed an increase in yield in a microscale amylose resin affinity purification. The distribution of the mutations was nonrandom, with six mutations clustered between residues 64 and 115 in the N-terminal half of the protein, and the remaining 13 mutations clustered between residues 303 and 367 in the C-terminal half. We obtained multiple isolates where the same residue was mutated, suggesting that we had isolated mutations in most of the residues that could be obtained using this method of mutagenesis and screening.

**Models for altered affinity** There are a number of models that could explain the increased binding of our MBP mutants. The previous work has focused on the fact that the open conformation of MBP is stabilized by a large area of contact between the two domains behind the hinge (Marvin and Hellinga [@CR9]; Telmer and Shilton [@CR18]). In the maltose-bound closed form, the corresponding areas of this interface are solvent-exposed. Alterations of MBP that disturb the interface alter the equilibrium toward the closed form, and affinity for maltodextrins is increased, since the energetic penalty for separating the interface is reduced or eliminated. One could also imagine that alterations that change the geometry of the hinge loops could alter the equilibrium between the open and closed conformations in a similar manner. Another way to affect ligand binding might be to alter the binding site, by mutating residues that form contacts to the ligand, or indirectly, by making nearby changes that move those residues slightly. Finally, MBP makes extensive contacts to the MalFGK transporter as it docks and releases its ligand, especially between domain I of MBP and the P2 loop of MalF (Oldham et al. [@CR13]). It is possible that these contacts induce a conformational change in MBP to reduce its affinity for the ligand, and mutations in MBP that disfavor this hypothetical shift might increase its affinity.

**Mutations that affect the interface behind the hinge** Several of our mutations, located between residues 300 and 330, can be rationalized by reference to the previous site-directed work and fit the model that biasing the conformational equilibrium towards the closed form increases MBP's affinity for maltodextrins. This region includes residues that were modified by Hellinga's lab (I329) and Shilton's lab (M321 and Q325). In fact, we obtained mutations in the latter two residues in our screen. These mutations interfere with the packing of the interface between the two domains that forms when MBP is in the open conformation. We predict that our mutation in A318 also falls in this category, and probably T93A, V302A, V302L, Y307C, N323Y, and N332I as well (Fig. [4](#Fig4){ref-type="fig"}). The T93 side chain is not part of the interface itself but rather is on the opposite side of helix 5 from F92, which makes van der Waals contacts with domain II in the open conformation. Likewise, the A302, Y307, N323 side chains are on the opposite sides of helix 13 and 14 that form part of the domain II surface of the interface. The K83R mutation does not offer an analogous rationale, but the K83 side chain undergoes an extensive remodeling during the open to closed transition, and it is possible that the arginine substitution has effects on the position of helix 5 as well. The side chain of N332 forms a link between the two domains by hydrogen bonding to the backbone carbonyl of A96 in the closed conformation and flexes with domain II as the conformation opens. While not directly part of the interface that forms as the conformation shifts to the open form, this hydrogen bond provides a unique way for domains I and II to communicate independent of the hinge regions, by linking the hinge motion to an alteration of the conformation of the loop between helices 14 and 15. It might be possible to test whether these mutations affect the equilibrium between the open and closed forms. NMR experiments using paramagnetic relaxation enhancement (PRE) have shown that in the absence of maltose, MBP exists as a rapidly exchanging mixture of ∼95% open and ∼5% closed form (Tang et al. [@CR17]). Using this technique on the mutant MBPs would allow one to measure the equilibrium between the open and closed forms directly. Fig. 4Residues where mutations may affect packing behind the hinge. **a** Cartoon of MBP showing residues where mutations were obtained. *Colors* as in Fig. [2](#Fig2){ref-type="fig"}, except labeled residues in *red*. **b** Surface representation of MBP in the closed conformation; *colors* as in (**a**). **c** Surface representation of MBP in the open conformation; *colors* as in (**a**)

**Mutations that affect the hinge** Several of our mutations are located in or directly adjacent to two of the hinge regions between domains I and II. The mutations V110I and S114L are in or near hinge region 1 (residues 110--113), and A312V and I317V are in or near hinge region 3 (residues 311--315). These mutations could also indirectly affect the packing of the interface behind the hinge, or they could affect the conformation of the hinge directly and thus alter the equilibrium between the open and closed conformations. The A312V and I317V mutations in particular suggest the latter possibility, as the A312 side chain is solvent exposed in the open conformation but rotates inward and forms van der Waals contacts with I317 in the closed conformation (Fig. [5](#Fig5){ref-type="fig"}). Again, NMR PRE experiments would allow one to assess directly the effect of the mutations on the conformational equilibrium. Fig. 5Position of A312 and I317. **a** Open (unliganded) conformation, PDB 1JW4 (Duan and Quiocho [@CR3]). **b** Closed (maltose bound) conformation

**Mutations away from the interface and hinge** The A63V, F67L, V343M, and ΔT2628 mutations are located farther from the hinges and the interface behind the hinges than the other mutations, suggesting a different mode of action. The A63V, F67L, and V343M mutations are adjacent to residues that form hydrogen bonds to the bound maltose, making it possible that they affect the binding pocket (Fig. [6](#Fig6){ref-type="fig"}). A63 is adjacent to W62, which forms a hydrogen bond to the bound maltose. F67 is on the face of helix 3 opposite to D65 and R66, which both also form hydrogen bonds to maltose. V343 forms van der Waals contacts with P154, which is adjacent to E153 and on the opposite face of helix 7 from Y155. E153 forms a hydrogen bond to maltose and the ring of Y155 stacks with the bound sugar. Paradoxically, the A63V and V343M mutations cause MBP2 to have a lower affinity for maltotriose, at least under the conditions used to measure affinity in this study. It is possible that these mutations have some effect on the kinetics of binding, for example, disproportionately decreasing the off rate of the ligand. However, we performed the Kd measurements under low ionic strength conditions (for comparison to values in the literature), as opposed to the moderate ionic strength we used in the affinity purification. Interestingly, the V343M mutation lies inside a subdomain consisting of residues 165 to183 and 334 to 369, which has been identified as the part of MBP that varies in position when binding maltose vs. longer maltodextrins (Quiocho et al. [@CR14]). Measuring Kds under a variety of conditions and increasing the number of forms of maltodextrin tested might clarify the effects of these mutations. The ΔT2628 mutation is a frameshift mutation that changes all the residues encoded by the synthetic linker following the portion of the *malE* gene used in this construct. Because of the large number of substitutions caused by this mutation, it will require quite a bit of further study to determine which of these substitutions affect the yield and solubility of MBP2 fusions. Fig. 6Location of mutations near the maltose binding site. *Colors* are as in Fig. [3](#Fig3){ref-type="fig"}, with hydrogen bonds indicated as *heavy dotted lines*, and *light dotted lines* indicating stacking interactions. **a** A63 and F67. **b** V343

**Effects on solubility enhancement** Most of the mutations we obtained reduce the ability of MBP2 to enhance the solubility of an MBP2--DHFR fusion protein. From the wide variety of mutations that have this behavior, it seems that this property of MBP2 is somewhat sensitive to alteration. These mutations did not cause MBP2 itself to become insoluble, as the mutant MBP2s had to have reasonable solubility to pass the screen for increased yield in the affinity purification. Fox et al. identified substitutions of glutamate for W232, Y242, and I317 as defective in enhancing the solubility of three aggregation-prone proteins fused to MBP (Fox et al. [@CR4]). These residues are all located at one end of the maltodextrin-binding cleft, potentially defining a site involved in enhancing solubility. However, the mutations in these residues all showed reduced stability as well, which led these researchers to conclude that it could also be some global defect in the folding of MBP that reduced the solubility enhancement. Our widely scattered mutations with the same property of reduced solubility enhancement only confuse the issue further, since they do not fit the model of a site on the surface of MBP that is important for this property. In fact, unlike the I317E mutation of Fox et al., our substitutions of valine and alanine for I317 did not reduce solubility enhancement. We think it is more likely that some of the mutations create disruptions of the folding pathway or possibly in the form or lifetime of a folding intermediate, which also disrupt the interaction between MBP and the protein to which it is fused.

**MBP mutants as fusion tags** Mutations that increase the yield from the amylose affinity purification and retain the ability of wild-type MBP to enhance the solubility of aggregation-prone proteins have obvious utility as potential fusion tags. Five of the 19 mutations retained the solubility enhancement seen with the MBP2-DHFR fusion. Three of these, A312V, I317V, and Q325R, have higher affinity for maltodextrins, most likely caused by shifting the equilibrium of MBP towards the closed conformation as discussed above. The reason for the increased yield of MBP2 fusions containing F67L and V343M is more obscure, although the F67 and V343 residues are located adjacent to residues that form bonds to the bound maltodextrin. The double mutants A312V I317V, and A312V I317A show an even higher affinity while maintaining solubility enhancement. The increased yield of these MBP derivatives when purified on immobilized amylose translates to an increase in yield of at least one fusion protein, the MBP-CBD fusion. But it is not clear that all MBP fusions that fail to bind to amylose do so in the same way. One can imagine that one mode of failure could be an interaction between MBP and the fused protein that alters the conformation of MBP. In this case, alterations that bias MBP towards the closed form may improve the binding of the fusion. However, another mode of failure might be misfolding of the fused protein, leading to a nonspecific interaction with the hydrophobic binding cleft of MBP that blocks access to the binding site. In this case, higher binding affinity might not lead to improved binding of the fusion protein. Future work will show how much these mutant MBPs with increased affinity will improve the success rate for purifying fusion proteins by amylose affinity chromatography.

Electronic supplementary material {#AppESM1}
---------------------------------

Below is the link to the electronic supplementary material.

###### 

(DOC 78 kb)

###### 

(DOC 8679 kb)

###### 

(DOC 1835 kb)

###### 

(DOC 69 kb)

We thank Ming Xu and David Waugh for providing plasmids and Jim Samuelson, Claude Maina, and especially Lise Raleigh for helpful comments on the manuscript.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
